Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,661
  • Shares Outstanding, K 13,054
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,200 K
  • EBIT $ -41 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 217.33% ( +45.48%)
  • Historical Volatility 70.72%
  • IV Percentile 42%
  • IV Rank 40.86%
  • IV High 472.50% on 12/13/23
  • IV Low 41.03% on 09/27/24
  • Put/Call Vol Ratio 0.47
  • Today's Volume 94
  • Volume Avg (30-Day) 704
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 17,380
  • Open Int (30-Day) 23,044

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.89
  • Prior Year -1.63
  • Growth Rate Est. (year over year) +61.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.04 +24.01%
on 10/15/24
10.54 -17.17%
on 10/28/24
+0.32 (+3.80%)
since 10/04/24
3-Month
7.04 +24.01%
on 10/15/24
10.54 -17.17%
on 10/28/24
+0.07 (+0.81%)
since 08/02/24
52-Week
4.53 +92.72%
on 07/02/24
22.49 -61.18%
on 12/27/23
+2.36 (+37.05%)
since 11/03/23

Most Recent Stories

More News
Annovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging...

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s...

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) to Present Alzheimer’s Research at CTAD Conference in Madrid

Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid...

ANVS : 8.73 (-3.96%)
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.73 (-3.96%)
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

ANVS : 8.73 (-3.96%)
Annovis Bio (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.73 (-3.96%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address...

ANVS : 8.73 (-3.96%)
JNJ : 158.24 (-1.18%)
MRK : 101.87 (-0.01%)
NVS : 110.52 (+1.07%)
GSK : 36.97 (+0.24%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

ANVS : 8.73 (-3.96%)
JNJ : 158.24 (-1.18%)
MRK : 101.87 (-0.01%)
NVS : 110.52 (+1.07%)
GSK : 36.97 (+0.24%)
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

ANVS : 8.73 (-3.96%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 9.66
2nd Resistance Point 9.44
1st Resistance Point 9.09
Last Price 8.73
1st Support Level 8.52
2nd Support Level 8.30
3rd Support Level 7.95

See More

52-Week High 22.49
Fibonacci 61.8% 15.63
Fibonacci 50% 13.51
Fibonacci 38.2% 11.39
Last Price 8.73
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar